SciSparc (SPRC) Stock

U.S. stocks traded slightly lower toward the end of trading, with the S&P 500 edging lower on Thursday.

FDA confirm s that SciSparc's study may proceed only a month after application submission

The intended selling valuation represents an increase of 47 % from the valuation at the time of SciSparc's initial investment in MitoCareX Bio

FDA confirm s that SciSparc's study may proceed following the application submission a month ago

Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel will take part in the trial

This innovative drug combination treatment focuses on boosting safety and efficacy in mental health and addiction care TEL AVIV, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd.

To date, SciSparc has advanced $4.25 million to Automax under the Bridge Loan agreement and amendments thereto

Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments TEL AVIV, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd.

TEL AVIV, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has announced the publication of its patent application under the international Patent Cooperation Treaty, for innovative combinations of ketamine and N-acylethanolamines.